| Literature DB >> 31513771 |
Amarendra Pegu1, Bhavesh Borate2, Yunda Huang3, Matthias G Pauthner4, Ann J Hessell5, Boris Julg6, Nicole A Doria-Rose1, Stephen D Schmidt1, Lindsay N Carpp2, Michelle D Cully1, Xuejun Chen1, George M Shaw7, Dan H Barouch8, Nancy L Haigwood5, Lawrence Corey2, Dennis R Burton9, Mario Roederer1, Peter B Gilbert10, John R Mascola11, Ying Huang12.
Abstract
Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection. With data from multiple non-human primate SHIV challenge studies that used single bNAbs, we conducted a meta-analysis to examine the relationship between predicted serum 50% neutralization titer (ID50) against the challenge virus and infection outcome. In a logistic model that adjusts for bNAb epitopes and challenge viruses, serum ID50 had a highly significant effect on infection risk (p < 0.001). The estimated ID50 to achieve 50%, 75%, and 95% protection was 91 (95% confidence interval [CI]: 55, 153), 219 (117, 410), and 685 (319, 1471), respectively. This analysis indicates that serum neutralizing titer against the relevant virus is a key parameter of protection and that protection from acquisition by a single bNAb might require substantial levels of neutralization at the time of exposure.Entities:
Keywords: SHIV challenge; broad neutralizing antibodies; correlates of protection; meta-analysis; non-human primate studies
Mesh：
Substances：
Year: 2019 PMID： 31513771 PMCID： PMC6755677 DOI： 10.1016/j.chom.2019.08.014
Source DB: PubMed Journal: Cell Host Microbe ISSN： 1931-3128 Impact factor: 21.023